BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+6.86%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$4.54B
AUM Growth
+$74.3M
(+1.7%)
Cap. Flow
-$108M
Cap. Flow
% of AUM
-2.39%
Top 10 Holdings %
Top 10 Hldgs %
49.79%
Holding
155
New
7
Increased
39
Reduced
61
Closed
13
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$39.2M |
| 2 |
Immunocore
IMCR
|
$38.3M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$36.5M |
| 4 |
Thermo Fisher Scientific
TMO
|
$20M |
| 5 |
Edgewise Therapeutics
EWTX
|
$17.7M |
Top Sells
| 1 |
Incyte
INCY
|
$35.5M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$29.9M |
| 3 |
Intuitive Surgical
ISRG
|
$25.6M |
| 4 |
Boston Scientific
BSX
|
$20M |
| 5 |
Cencora
COR
|
$19M |
Sector Composition
| 1 | Healthcare | 99.88% |
| 2 | Technology | 0.01% |
| 3 | Consumer Discretionary | 0.01% |
| 4 | Communication Services | 0.01% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
VanEck Gold Miners ETF
GDX
$19.4B
| $1.36M | 0.03% |
26,200
| – | – |
|
102
Rhythm Pharmaceuticals
RYTM
$6.88B
| $1.32M | 0.03% |
20,906
+5,356
| +34% | +$338K |
|
103
Protagonist Therapeutics
PTGX
$3.62B
| $1.08M | 0.02% |
19,472
+1,850
| +10% | +$102K |
|
|
BBNX
104
Beta Bionics, Inc. Common Stock
BBNX
$865M
| $973K | 0.02% |
66,825
| – | – |
|
105
Certara
CERT
$1.68B
| $956K | 0.02% |
81,740
| – | – |
|
106
Summit Therapeutics
SMMT
$17.5B
| $888K | 0.02% |
41,738
-25,947
| -38% | -$552K |
|
107
iShares Russell 2000 ETF
IWM
$67B
| $496K | 0.01% |
2,300
| – | – |
|
108
BridgeBio Pharma
BBIO
$9.82B
| $449K | 0.01% |
10,400
| – | – |
|
109
Novo Nordisk
NVO
$251B
| $449K | 0.01% |
+6,500
| New | +$449K |
|
110
Merus
MRUS
$4.92B
| $408K | 0.01% |
7,765
-235
| -3% | -$12.4K |
|
111
Exelixis
EXEL
$9.91B
| $375K | 0.01% |
8,500
| – | – |
|
112
NewAmsterdam Pharma
NAMS
$2.8B
| $372K | 0.01% |
20,555
-1,245
| -6% | -$22.5K |
|
113
Arcutis Biotherapeutics
ARQT
$1.95B
| $337K | 0.01% |
24,008
-11,692
| -33% | -$164K |
|
114
Madrigal Pharmaceuticals
MDGL
$9.55B
| $333K | 0.01% |
1,100
| – | – |
|
115
ADMA Biologics
ADMA
$3.99B
| $308K | 0.01% |
16,900
| – | – |
|
116
Planet Fitness
PLNT
$8.64B
| $294K | 0.01% |
+2,700
| New | +$294K |
|
117
uniQure
QURE
$945M
| $273K | 0.01% |
19,610
-2,890
| -13% | -$40.3K |
|
118
Travere Therapeutics
TVTX
$1.81B
| $271K | 0.01% |
18,303
-4,797
| -21% | -$71K |
|
|
CAI
119
Caris Life Sciences, Inc. Common Stock
CAI
$10.1B
| $267K | 0.01% |
+10,000
| New | +$267K |
|
120
Alphabet (Google) Class A
GOOGL
$2.78T
| $256K | 0.01% |
1,450
+350
| +32% | +$61.7K |
|
121
Amazon
AMZN
$2.5T
| $252K | 0.01% |
1,150
+250
| +28% | +$54.8K |
|
|
MTSR
122
Metsera, Inc. Common Stock
MTSR
$3.71B
| $222K | ﹤0.01% |
+7,800
| New | +$222K |
|
123
Mineralys Therapeutics
MLYS
$2.04B
| $210K | ﹤0.01% |
15,556
-943
| -6% | -$12.8K |
|
124
BellRing Brands
BRBR
$5.34B
| $203K | ﹤0.01% |
3,500
+2,100
| +150% | +$122K |
|
125
Arcellx
ACLX
$3.93B
| $198K | ﹤0.01% |
3,000
| – | – |
|